瑞戈非尼治疗成人转移性骨肉瘤的疗效与安全性:非对照、随机、双盲、安慰剂对照2期研究
REGOBONE研究的骨肉瘤队列,纳入43例既往接受过1–2线化疗后进展的转移性骨肉瘤成人患者,按2:1随机接受瑞戈非尼或安慰剂。可评估疗效的38例中,瑞戈非尼组26例有17例(65%)8周时无进展,安慰剂组12例均无进展。瑞戈非尼组7例(24%)发生治疗相关严重不良事件,未发生治疗相关死亡。
要点
- 瑞戈非尼组8周无进展比例为65%(17/26),安慰剂组为0%(0/12)。
- 瑞戈非尼组7/29例(24%)发生治疗相关严重不良事件,安慰剂组0/14例。
- 常见≥3级治疗相关不良事件包括高血压、手足皮肤反应、乏力、低磷血症和胸痛。
核心结论
- 瑞戈非尼在常规化疗失败后的复发、进展、转移性骨肉瘤成人患者中显示出有临床意义的抗肿瘤活性,对延缓疾病进展有正面作用。
- 作者认为瑞戈非尼应进一步在晚期疾病以及可能更早期的高复发风险患者中评估。
- 作者认为瑞戈非尼可能作为标准化疗的补充药物在骨肉瘤治疗中发挥重要作用。
研究设计与样本
- 非对照、随机、双盲、安慰剂对照2期试验,为REGOBONE研究四个平行独立队列中的骨肉瘤队列。
- 纳入年龄≥10岁、组织学确诊骨肉瘤、转移性疾病经1–2线化疗后进展、ECOG体能状态0或1的患者。
- 按2:1随机分配至口服瑞戈非尼160 mg/天(每28天用21天)或匹配安慰剂,两组均接受最佳支持治疗;随机按入组年龄(<18岁 vs ≥18岁)分层。
- 2014年10月10日至2017年4月4日从13家法国综合癌症中心入组43例成人患者;5例因重大方案违背被排除,38例可评估疗效(安慰剂组12例,瑞戈非尼组26例)。
- 主要终点为8周时无疾病进展的患者比例;分析采用改良意向治疗,安全性分析纳入所有接受至少一剂研究药物的患者。
主要发现
- 瑞戈非尼组26例中17例(65%;单侧95% CI 47%)8周时无进展,安慰剂组12例中0例无进展。
- 安慰剂组10例在中枢确认疾病进展后交叉接受开放标签瑞戈非尼。
- 瑞戈非尼组29例中7例(24%)发生13起治疗相关严重不良事件,安慰剂组14例中0例。
- 双盲期最常见≥3级治疗相关不良事件:高血压(瑞戈非尼组7/29例[24%] vs 安慰剂组0例)、手足皮肤反应(3/29例[10%] vs 0例)、乏力(3/29例[10%] vs 1/14例[3%])、低磷血症(3/29例[10%] vs 0例)、胸痛(3/29例[10%] vs 0例)。
- 未发生治疗相关死亡。
关键数值与推荐
- 主要终点:8周无进展比例瑞戈非尼组65%(17/26;单侧95% CI 47%)vs 安慰剂组0%(0/12)。
- 治疗相关严重不良事件:瑞戈非尼组7/29例(24%)vs 安慰剂组0/14例。
- ≥3级治疗相关不良事件:高血压瑞戈非尼组7/29例(24%)vs 安慰剂组0例;手足皮肤反应3/29例(10%)vs 0例;乏力3/29例(10%)vs 1/14例(3%);低磷血症3/29例(10%)vs 0例;胸痛3/29例(10%)vs 0例。
- 治疗相关死亡:瑞戈非尼组0例,安慰剂组0例。
临床怎么用
- 作者认为瑞戈非尼在常规化疗失败后的复发、进展、转移性骨肉瘤成人患者中显示出有临床意义的抗肿瘤活性,对延缓疾病进展有正面作用。
- 作者建议瑞戈非尼应进一步在晚期疾病以及可能更早期的高复发风险患者中评估。
- 作者认为瑞戈非尼可能作为标准化疗的补充药物在骨肉瘤治疗中发挥重要作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. In this Article, we report the results of the osteosarcoma cohort. METHODS: In this non-comparative, double-blind, placebo-controlled, phase 2 trial, patients aged 10 years or older with histologically confirmed osteosarcoma whose disease had progressed after treatment with one to two previous lines of chemotherapy for metastatic disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled. Patients were randomly assigned (2:1) to receive either oral regorafenib (160 mg/day, for 21 of 28 days) or matching placebo. Patients in both groups also received best supportive care. Randomisation was done using a web-based system and was stratified (permuted block) by age at inclusion (<18 vs ≥18 years old). Investigators and patients were masked to treatment allocation. Patients in the placebo group, after centrally confirmed progressive disease, could cross over to receive regorafenib. The primary endpoint was the proportion of patients without disease progression at 8 weeks. Analyses were done by modified intention to treat (ie, patients without any major entry criteria violation who initiated masked study drug treatment were included). All participants who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT02389244, and the results presented here are the final analysis of the osteosarcoma cohort (others cohorts are ongoing). FINDINGS: Between Oct 10, 2014, and April 4, 2017, 43 adult patients were enrolled from 13 French comprehensive cancer centres. All patients received at least one dose of assigned treatment and were evaluable for safety; five patients were excluded for major protocol violations (two in the placebo group and three in the regorafenib group), leaving 38 patients who were evaluable for efficacy (12 in the placebo group and 26 in the regorafenib group). 17 of 26 patients (65%; one-sided 95% CI 47%) in the regorafenib group were non-progressive at 8 weeks compared with no patients in the placebo group. Ten patients in the placebo group crossed over to receive open-label regorafenib after centrally confirmed disease progression. 13 treatment-related serious adverse events occurred in seven (24%) of 29 patients in the regorafenib group versus none of 14 patients in the placebo group. The most common grade 3 or worse treatment-related adverse events during the double-blind period of treatment included hypertension (in seven [24%] of 29 patients in the regorafenib group vs none in the placebo group), hand-foot skin reaction (three [10%] vs none), fatigue (three [10%] vs one [3%]), hypophosphataemia (three [10%] vs none), and chest pain (three [10%] vs none). No treatment-related deaths occurred. INTERPRETATION: Regorafenib demonstrated clinically meaningful antitumour activity in adult patients with recurrent, progressive, metastatic osteosarcoma after failure of conventional chemotherapy, with a positive effect on delaying disease progression. Regorafenib should be further evaluated in the setting of advanced disease as well as potentially earlier in the disease course for patients at high risk of relapse. Regorafenib might have an important therapeutic role as an agent complementary to standard cytotoxic chemotherapy in the therapeutic armamentarium against osteosarcoma. FUNDING: Bayer HealthCare.
引用
- Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2018. PMID: 30477937. doi:10.1016/S1470-2045(18)30742-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。